A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
|Slideshows|February 8, 2019
5 Head-Scratching Prescriptions Sent to the Pharmacy
Author(s)Alex Evans, PharmD, BCGP
Unclear prescriptions can trigger a cascade of serious events. See if these 5 caught by one pharmacy team look familiar, and beware.
Advertisement
Any pharmacist that has been practicing for a while has seen their fair share of prescription gaffes. Of course medication errors are a serious issue and unclear prescriptions can contribute, but today I am going to keep it light with a review of 5 of the most “notable” prescriptions I have seen recently. Most of them, of course, were followed up with a phone call to the doctor’s office! Click through the quick slideshow to get more details and see if any of these “head scratchers” look familiar to you.
Advertisement
Related to this article
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
New American Society of Hematology guidelines raise ferritin cutoffs to catch iron deficiency sooner, including pregnancy and inflammation, and add TSAT for clearer diagnosis.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
The FDA accepted Organon’s MIUDELLA supplemental application, but the proposed change, supporting data, and review timeline remain undisclosed.
Advertisement
Advertisement
Trending on Patient Care Online
1
Lumateperone Reduces Acute Mania Symptoms in Phase 3 Bipolar I Trial
2
Endocrine Society Obesity Statement Calls for Goals Beyond Weight Loss
3
Clinical Inertia and Poor Measurement Technique Undermine BP Control
4
Cuffless Blood Pressure Devices Fall Short of Clinical Standards
5